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Abstract-The results of a cost-effectiveness analysis of cervical cancer screening in The Netherlands are 
reported, emphasizing the analysis of the costs of screening and consequent diagnosis and treatment. Many 
organized screening policies are evaluated, differing in age-range and interval between screens. The cost 
estimates are based on organization charts, file studies and tariffs. The costs of screening itself are by far 
the most important cost component. Screening increases the costs of diagnosis. Costs for primary 
treatment only rise for large screening policies. Screening causes savings in costs of terminal treatment, 
but these are small compared with the costs of screening. 
The costs per life-year gained for the most efficient policies amount to DFL 24,000 for the policy with 
7 invitations per woman in a lifetime and rise considerably in case of more than 10 invitations. Cervical 
cancer screening appears to be less cost-effective than breast cancer screening, but compared with other 
services the results are comparatively good. 
Implementing one of the efficient organized screening policies and discouraging spontaneous creening 
beyond that schedule leads to considerable savings. Moreover, many organized policies which are not 
efficient are still superior to spontaneous creening. 
Key Words-economic evaluation, costs, cost-effectiveness, cervical cancer, mass screening 
INTRODUCTION 
In The Netherlands 300 women per year die from 
cervical cancer, i.e. 0.5% of total female mortality. 
Symptoms of cervical cancer only occur when the 
cancer is already invasive. The pre-invasive stages of 
cervical cancer last on average about 15 years and can 
be detected by taking a Pap-smear. Almost 100% of 
the women with early detected pre-invasive stages can 
be cured. 
A considerable part of the pre-invasive stages will 
not become invasive but will disappear (regress) 
spontaneously, especially in younger ages. Neither 
the smear nor further diagnosis can discern regressive 
from progressive pre-invasive stages, so any screening 
policy inevitably causes diagnosis and treatment and 
costs for women who would never have developed 
invasive cervical cancer. Taking Pap-smears has 
proved to be effective from the medical point of view: 
it can reduce cervical cancer mortality [l]. 
Discussion remains about the best screening policy: 
At what ages should women be screened? What is 
the appropriate interval between successive screens? 
Should women be invited? Who must take the 
smears. specially trained women or general prac- 
titioners and gynaecologists? To answer these ques- 
tions it is necessary to estimate both health effects and 
costs of all possible courses of action. Moreover, 
costs and health effects of screening for cervical 
cancer should be evaluated in relation to other health 
services, given limited resources. 
*Address correpondence to: M. A. Koopmanschap, Depart- 
ment of Public Health and Social Medicine, Erasmus 
University Rotterdam. P.O. Box 1738, 3000 DR Rotter- 
dam. The Netherlands. 
The study on which this article has been based aims 
at determining which policies of cervical cancer 
screening in The Netherlands generate the best results 
in terms of health effects and costs [2]. To this end a 
prospective cost-effective analysis has been carried 
out in which epidemiological, medical and economic 
aspects were studied. This article describes the eco- 
nomic part and focuses on the following items: 
-the costs of screening itself for various policies; 
-the influence of screening on costs of diagnosis 
and treatment; 
-the cost-effectiveness of the most favourable 
policies, as compared with other health care 
services. 
MATERIALS AND METHODS 
In general 
During the last decade in The Netherlands, as in 
many other countries, early detection of cervical 
cancer was achieved in two ways. A screening pro- 
gramme was in operation for all women aged 35-54, 
who were invited at 3-year intervals. At the same time 
gynaecologists and general practitioners have taken 
many. smears, especially from younger women, with- 
out fixed intervals. As a result many women were 
screened very often. The efficiency of this combi- 
nation of organized and spontaneous screening has 
been questioned. 
In order to make recommendations about age- 
groups and intervals it is necessary to estimate costs 
and health effects of strategies in which only ‘organ- 
ized’ screening is performed. This means that women 
are invited regularly. The screening is performed 
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exclusively by trained female personnel. No further impact on diagnosis and treatment with the relevant 
smears are taken. cost-estimates. 
To estimate the impact of ‘organization’, costs and 
effects were also calculated for cases in which only 
spontaneous screening was performed. Early detec- 
tion was by general practitioners and gynaecologists 
only, according to the distribution and frequency of 
smears as observed in The Netherlands during 
1985-1987. 
With respect to organized screening, cost and 
health effects were calculated for about 100 policies. 
The number of invitations per woman varied between 
3 and 25, the interval between two invitations ranged 
from 15 to 2 years. The age-group invited varied 
between the ages of 20 and 75. Results were com- 
pared with the estimated costs and effects for the 
(hypothetical) situation where no early detection 
takes place: the zero-option. 
The most important health effect of cervical cancer 
screening is the reduction in mortality, expressed in 
the number of life-years gained compared with the 
zero-option. From the total set of policies those with 
a maximum of life-years gained for a given level of 
costs were identified as efficient policies. Figure 1 
shows the incremental costs and the life-years gained 
for all simulated policies. The marked points indicate 
efficient policies. ‘The upper-left quadrant of these 
points is empty with neither policies producing more 
life-years gained for the same costs nor policies saving 
more life-years less expensively. 
In the rest of this paper results will only be 
presented for a limited number of efficient organized 
screening policies and one variant of spontaneous 
screening. 
A model for cervical cancer and the impact of 
screening on morbidity and mortality was developed. 
The micro-simulation programme MISCAN was 
used to calculate screening results and the effects of 
screening [3,4]. First, the model was fitted to data 
from the three Dutch pilot regions where organized 
screening took place during 1976-1984. Model as- 
sumptions about sensitivity of the Pap-smear and 
regression and duration of the pre-invasive disease 
stages were derived which offered a satisfactory fit 
with data concerning screen detected pre-invasive and 
invasive cases, interval cancers and mortality. 
Cost calculations 
All possible costs and savings that screening poli- 
cies bring about were identified and measured, taking 
the concept of social costs as our point of departure. 
This included non-financial costs and costs which do 
not fall upon the medical sector, but excluded value 
added tax. The costs of screening itself were derived 
by estimating the quantities and costs of each input 
of the screening programme. This resulted in cost 
functions reflecting the influence of fixed and variable 
costs and economies of scale. 
Next, the model was used to predict the health 
effects and costs of the policies. Data for the assump- 
tions concerning organization and costs were col- 
lected by numerous interviews and analysis of cost 
accounts. They were integrated into the model by 
combining the predicted numbers of screens and the 
The cost of diagnosis and treatment have been 
approximated by the tariffs charged (1987) in The 
Netherlands. An analysis of the true resource costs 
was beyond the scope of this study. 
For each policy MISCAN calculated for each year 
the number of women invited, the number of women 
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Fig. 1. Incremental social costs and life-years gained for about 100 different organized cervical cancer 
screening policies. Screening during 1988-2015. Discount rate 5%. The marked points indicate the subset 
of efficient policies. 
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Table I. Financial costs of screening per year for organized screening 
policies with 250,000 and 1,000,000 smears per year and spontaneous 
screening, in millions DFL (including 4% repeated smears, attcn- 
dance rate 65%) 
Smears per 
year ( x 1000) 
Organized policies Spontaneous 
250 (%) 1000 (%) 910 (%) 
Coordination 
Invitations 
and results 
Smear taking 
Cytological 
evaluation 
Registration 
Total costs 
of screening 
Per smear 
3.4 (24) 4.3 (IO) - 
1.1(8) 4.4(10) 1.2(3) 
3.5 (24) 13.3 (31) 14.3 (40) 
5.6 (39) 19.2 (45) 18.4 (52) 
0.8 (6) 1.5(4) 1.7 (5) 
14.4 (100) 42.7(M) 35.6(100) 
(in guilders) 58 43 39 
screened and the number of women needing diagnosis 
and/or therapy in various degrees. These outcomes, 
combined with the cost functions and tariffs pro- 
duced the annual costs. Only after a considerable 
period the health effects of screening on cervical 
cancer become visible, while the costs of screening 
are important from the start. To permit adequate 
evaluation, the screening programme was assumed to 
be in operation during 1988-2015. After the year 
2015, the terminated programme will still cause 
health effects and changes in costs of diagnosis and 
treatment; these were calculated until 2088. Costs and 
effects were discounted to present values for 1988 
with a discount rate of So!, stipulated by the Dutch 
government [S] and several health economists [6]. The 
estimated annual financial costs for government and 
insurers, including value added tax, will also be 
presented. 
A fraction of women screened had a suspicious 
smear, leading to diagnosis and, if necessary, treat- 
ment. Therefore three categories of costs were rel- 
evant: costs for screening, diagnosis and treatment. 
Costs of screening 
The organization of the cervical mass screening in 
the three Dutch pilot regions and expert opinions 
about future developments were used to draw the 
outline of an efficient nationwide organization. This 
outline is only a tool to assess all relevant costs. The 
activities were carried out at three levels: local, 
regional and national (Table 1). 
Local level. Each municipality sent a first invitation 
to the women in turn, by means of the up to date 
population registry. The women were screened in 
their municipality by a team of three trained smear- 
takers. The yearly capacity per team ranged from 
19,000 (mobile unit) to 20,000 (static centre) smears. 
For a static centre the material costs were relatively 
low; use of a mobile unit increased the cost of taking 
smears by at least 25%. The number of static and 
mobile units depended on the population density and 
the number of women screened. The time and travel 
costs of the women attending were relevant social 
costs (see Table 2). The average time for travelling 
and screening was estimated at 50 min and was 
valued by 25% of the average net labour income per 
labour hour per household, according to binding 
advices [7]. Travel costs were estimated on the basis 
of public transport tariffs. 
Regional level. With respect to cancer prevention 
The Netherlands was divided into 9 regions, each 
with on average about 800,000 female inhabitants. 
One coordination centre per region managed the 
screening teams, took care of local publicity and 
informed municipalities about the invitations. The 
centre sent test results to all women participating and 
re-invited non-participants. In cooperation with the 
cytological laboratory, quality control of the smears 
and training of the smear-takers was carried out. The 
centre was staffed by a manager, a medical consultant 
and administrative personnel. The workload and the 
costs varied according to the size of the programme. 
The cytological laboratory evaluated the smears 
and registered the test results in a local data-base con- 
nected to a national data-base. On average, full time 
analysts evaluated approx. 7200 smears annually. Per 
50,000 smears one senior analyst, one pathologist and 
two administrative employees are needed. Economies 
of scale existed for the costs of supervising and 
administrative personnel and part of the material 
costs. 
National level. One centre took care of the national 
coordination and public relations. Using regional 
reports the policy is monitored and adapted if neces- 
sary. These costs did not depend on programme size. 
The costs of registration consisted of costs for the 
national data-base, costs of training the laboratory 
personnel and costs of local computer facilities. The 
national data-base also registered results of other 
pathological examinations, so the costs were only 
partially included. 
Spontaneous creening. This incurred no costs of 
coordination and invitation. To estimate the costs of 
smear-taking, we assumed that all smears were taken 
Table 2. Present value for 1988 of social costs of screening for three dfcicnt policies and spontaneous 
screening during 1988-2015 in millions DFL. Discount rate 5% (including 4% repeat smears, attendance 
rate 65%). Invitation schedule, number of invitations/age-range/interval 
Efficient policies screening 
Invitation schedule 7137-7316 10127-7215 16126-7413 - 
Average number of smears ( x 1000) 390 610 975 910 
Coordination 63 61 75 - 
Invitations and results 23 35 56 18 
Smear taking 77 118 187 204 
Cytological evaluation 120 179 280 270 
Registration 13 16 20 23 
Time and travel costs 29 45 72 63 
Total costs of screening 325 461 691 578 
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by general practitioners and calculated the labour 
costs of the general practitioner, the assistant and the 
material costs. Although this resulted in under- 
estimating the costs since gynaecologists also took 
many smears which were more expensive, on the 
other hand, during a visit other medical activities may 
be performed as well, so only part of the costs should 
be attributed to the smear. 
Costs of diagnosis and treatment 
There are two situations where diagnosis and treat- 
ment take place: after an abnormal preventative 
smear or in case of possible symptoms of cervical 
cancer. In the zero-option, without any early detec- 
tion, costs of diagnosis and treatment are only im- 
portant for women with symptoms. In our study a 
detailed scheme was constructed to determine which 
diagnostic and therapeutic procedures took place for 
women having a suspicious smear. This scheme was 
subdivided by stage of disease and enabled us to 
calculate changes in number and types of procedures 
and costs when the stage-distribution of diagnosed 
(pre)-cancers alters due to screening. For more details 
see Ref. [8]. 
RESULTS 
Costs of screening 
In Table 1 the annual financial costs of screening 
are summarized for two different sizes of policies. 
Table 2 shows the present value of the social costs of 
policies, operational during 1988-2015, taking into 
account the demographic situation. The Results in 
Tables 1 and 2 include the costs of 4% repeat smears 
taken because of insufficient quality of the first smear. 
The average attendance rate assumed is 65%, as 
observed in the pilot regions. The total financial costs 
per smear range from DFL 58 for 250.000 annual 
smears to DFL 43 for 1 ,OOO,OOO smears per year. The 
economies of scale are considerable, chiefly because 
the costs for coordination and registration are almost 
fixed. The costs of coordination, registration and 
sending of invitations and test results form a substan- 
tial part of the total screening costs (15-30%), what- 
ever the size of the policy. The ‘medical activities’ 
smear-taking and cytological evaluation, make up 
60-75% of the total costs. Time and travel costs 
account for 10% of the social costs of the screening 
(see Table 2). 
The last column in Tables 1 and 2 indicates the 
costs of spontaneous screening on a scale of approx. 
910,000 smears per year resembling the situation in 
The Netherlands during 1985-1987. The costs per 
smear are relatively low, the total costs of the spon- 
taneous screening are considerable, due to the large 
number of smears. 
Costs of diagnosis and treatment 
The costs of diagnosis and treatment were com- 
puted by combining the relevant number of women 
with the schemes for diagnosis and treatment and the 
tariffs charged. Figure 2 depicts the extra costs and 
savings for diagnosis and treatment induced by 
two different organized screening policies, compared 
with the zero-option. The data are not discounted 
(Table 3 will show discounted costs). 
Positive smears induce costs for diagnosis (DS). 
The more screening, the more positive test results, 
the higher the costs of diagnosis. Due to screening 
the number of women with symptoms diminishes, 
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Fig. 2. Extra social costs and savings for diagnosis and treatment compared with no early detection, 
for two efficient policies, in millions DFL. No discounting. ds = extra costs of diagnosis induced by 
screening; dc = savings in costs of diagnosis; pts = extra costs of primary treatment induced by screening; 
ptc = savings in costs of primary treatment; tt = savings in costs of terminal treatment. 
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Table 3. Present value for 1988 of K&I costs of screening, diagnosis, treatment and incremental 
costs for three efficient policies, spontaneous creening and no early detection in millions DFL. 
Period 1988-2088. Discount rate 5% 
costs 
Efficient policies 
Spontaneous No early 
7 10 16 screening detection . 
Screening 325 461 691 578 0 
Diagnosis 27 39 54 47 1 
Primary treatment 165 182 192 200 163 
Terminal treatment 78 73 68 84 101 
Total costs 595 754 1005 909 211 
Total incremental costs 324 483 735 638 - 
causing a small saving (DC). Screening increases the 
number of women with diagnosed precancers, which 
incurs costs for primary treatment (PTS). These costs 
consist of two parts: costs for women detected by 
screening, who would develop invasive cancer with- 
out screening and costs for women with regressive 
lesions which never would become invasive. The 
prevention of invasive cancers permits substantial 
savings on primary treatment (PTC). With more 
intensive screening savings (PTC) rise, but the in- 
crease of the extra costs (PTS) is even sharper, since 
the proportion of regressive lesions increases. 
The reduction of invasive cancers causes a decrease 
in mortality. The savings on terminal treatment (TT) 
increase gradually with more intensive screening. 
The savings induced by screening lag behind the 
extra costs. Discounting gives the results shown in 
Table 3. The discounted costs of diagnosis increases, 
particularly with more intensive screening. Screening 
with 7 invitations leaves the costs of primary treat- 
ment on balance unaltered. Intensifying screening 
means that the extra costs of primary treatment 
outweigh the savings at an increasing rate. Terminal 
treatment still produces savings, although discount- 
ing diminishes the absolute level. Spontaneous 
screening generates a high level of costs for primary 
treatment but this does not produce large savings on 
terminal treatment because the mortality reduction is 
relatively small. 
Total costs 
The costs of screening are by far the most import- 
ant part of the total costs, especially for more inten- 
sive screening programmes. Costs of diagnosis and 
treatment are relatively small. Savings are to be 
expected on terminal treatment, but are rather 
modest. The total incremental costs compared with 
the zero-option range from 324 million DFL in the 
case of 7 invitations per woman to 735 million DFL 
if women are invited 16 times. The incrementalcosts 
of spontaneous screening exceeds 600 million DFL. 
Cost-effectiveness 
The cost-effectiveness of the policies is expressed as 
the incremental social costs per life-year gained. 
Table 4 shows the results for three efficient organized 
screening policies and one level of spontaneous 
screening. 
The additional health effects of intensifying a 
screening policy diminish rapidly. An increase from 7 
to .lO invitations per woman results in an additional 
number of 3900 life-years gained, as an increase from 
10 to 16 invitations only saves 2900 life-years extra. 
The incremental costs rise faster, more or less propor- 
tional to the number of invitations. Consequently the 
incremental costs per life-year gained increases if 
screening is intensified. The efficient policy with 7 
invitations per woman costs about 24,000 guilders per 
life-year gained. For the policy with 10 invitations the 
cost amounts to 28,000 guilders. For policies with 
more than 10 invitations the cost-effectiveness deteri- 
orates rapidly. 
Spontaneous screening on a scale reflecting recent 
Dutch practice generates a number of life-years 
gained equal to the efficient policy with 7 invitations, 
but the social costs are twice as high, When spon- 
taneous screening takes place data indicate that part 
of the women, especially younger women, is screened 
very frequently (yearly), whereas the rest of the 
women only rarely has a screen and hence the health 
effects are limited. If no spontaneous screening is 
performed and the efficient policy with 7 invitations 
were to be implemented, 20 million guilders per year 
(financial costs) could be saved. 
For a comparison of the efficient policies as well 
as for comparison with other health interventions, 
the marginal cost-effectiveness i  important. Table 4 
shows that the extra costs per extra life-year gained 
rise rapidly when switching from 7 to 10 invitations. 
Further intensifying the policy yields a considerable 
increase in marginal cost-effectiveness. 
To ensure a rational health services budget, cost- 
effectiveness hould be compared with other services. 
Table 4. Present values for 1988 of incremental social costs, life years gained and cost-effectiveness 
of three efficient screening policies and spontaneous creening. All outcomes are compared with the 
zero-ootion. Discount rate 5% 
Efficient policies 
Saontaneous 
7 10 16 -;creening 
Incremental social costs (millions DFL) 324 483 735 638 
Life-years gained ( x 1000) 13.3 11.2 20.1 13.4 
Costs per life-year gained ( x 1000 DFL) 24.3 28 36.5 41.6 
Margmal costs per life-year gained 
( x 1000 DFL) 24.3 40.8 86.9 - 
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Table 5. Influence of the discount rate on social costs, health effects 
and cost-effectiveness for the efficient policy with 7 invitations. The 
percentages compared-with no discounting arc in parentheses 
Discount rate 
Incremental costs 
(millions DFL) 
Life-years gained 
Costs per life-year gained 
(DFL) 
0% 5% 7% 
510 324 277 
(100%) (64%) (54%) 
68,300 13,300 7900 
(100%) (28%) (12%) 
7500 24,300 35,000 
(100%) (324%) (467%) 
A recent Dutch study of breast cancer screening using 
the same methodological assumptions [9] reported 
that breast cancer screening with 10 invitations per 
woman cost DFL 9700 per life-year gained. Further 
extension to 15 invitations cost DFL 25,800 per extra 
life-year gained. For the same number of invitations 
cervical cancer screening appears to be less attractive. 
Comparison with other health care services is difficult 
because of methodological differences between analy- 
ses. However, in Torrance’s widely cited table of 
cost-effectiveness ratio’s [lo] the efficient policies of 
cervical cancer screening with 7 or 10 invitations have 
an intermediate cost-effectiveness ratio. 
Sensitivity analysis 
Cytological evaluation. On the basis of our recently 
collected data a workload of 7200 smears per analyst 
per year has been estimated. Assuming that the 
cytology is regionally concentrated so that expertise 
can attain a sufficient level, our preliminary view is 
that 7200 is a reasonable workload. 
However, Dutch pathologists recently agreed [l l] 
that if 85% of the smears are preventive (15% of the 
smears are from women with symptoms) the optimal 
workload to ‘aim for is 5000 smears. With 100% 
preventative smears the workload would then be 
about 5500 smears. The costs of cytological evalu- 
ation would increase 15%, total costs of screening 
and the costs per life-year gained would rise 6%, 
compared with the results presented. This workload 
forms the subject of a future study. 
Discount rate. Results were also calculated using 
discount rates of 0 and 7%. Table 5 shows that 
discounting at a rate of 7% implies that the number 
of discounted life-years gained is only 12% of the 
amount without discounting, whereas the incremen- 
tal costs are still 54% of the amount without dis- 
counting. This confirms the importance of using a 
uniform discount rate in cost-effectiveness analyses. 
DISCUSSION 
Quality of life 
Comparison of cervical cancer screening with other 
health care services should be based on costs per 
quality of life-year gained. Our study did not produce 
QALY-estimates, but two extreme variants were 
calculated to indicate the possible impact of quality 
adjustments. In the ‘weak variant’ the quality of life 
reductions for invasive cancer or being treated by 
hysterectomy or radiotherapy are assumed to be 
modest. In the ‘strong variant’ these reductions are 
greater and they are also applied to larger groups of 
women in less severe circumstances uch as women 
with false-positive smears [2]. 
For efficient policy with 7 invitations the weak 
variant produces slightly more QALY’s gained than 
without adjustment. The strong variant results in 
about 25% less QALY’s. We expect that empirical 
research will produce estimates between these two 
extremes. 
Other studies 
Comparison with other studies of cervical cancer 
screening is difficult for three reasons. First, the 
number of serious cost-effectiveness analyses on this 
subject is very limited. Second, some of them deal 
with the epidemiology in detail but use only super- 
ficial economic assumptions [12]. Third, the only 
detailed study of economic aspects [13] focused on 
screening in a clinical setting which is different 
from a mass screening programme with respect to 
organization and costs. 
Organized and spontaneous screening 
In The Netherlands, as in many other countries, a 
combination of organized and spontaneous creening 
existed in the past and will probably continue in the 
future. The results of some of these combinations 
were calculated. They incur high costs for an inter- 
mediate level of health effects, because some women 
are screened in both contexts. 
Screening in the future 
In The Netherlands the organized screening pro- 
gramme terminated in 1984 was resumed in 1989. 
Women are invited from age 35 up to age 53 with a 
3-year interval, this in spite of our findings that such 
a schedule is not efficient (in efficient policies screen- 
ing is performed up to 70 years). The costs per 
life-year gained amount to DFL 36,400, assuming the 
organization described in this paper. However, in the 
new setting the general practitioners take the smears; 
the rest of the organization is not yet entirely estab- 
lished. Our preliminary research indicates that if the 
coordination of the activities of 6000 general prac- 
titioners and quality control is performed seriously 
the costs will not be much lower than reported here. 
The level of health effects is very uncertain, because 
the attendance rate and the quality of smears in the 
new setting remain unknown. 
Our findings did not result immediately in any 
policy change. The government department of health 
care has maintained its old policy for organizational 
reasons. Further study of the effectiveness of screen- 
ing in women older than age 55 will be carried out, 
which may influence the policy in the near future. 
CONCLUSIONS 
A large part of the costs of cervical cancer screen- 
ing programmes consist of the costs of screening 
itself. Screening enlarges the costs of diagnosis. Costs 
of primary treatment remain unaltered for efficient 
policies with 10 or less invitations, but increase in case 
of more invitations. Costs of terminal treatment 
decline. 
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The incremental costs per life-year gained are 
about 24,000 guilders for the efficient policy with 
7 invitations and increases to 36,000 in case of 16 
invitations per woman. The substantial influence of 
the discount rate on the cost-effectiveness confirms 
the need of uniform methodology. 
Cervical cancer screening is less cost-effective than 
breast cancer screening on the same scale. Compared 
with other health care services the efficient policies 
with 7 or 10 mvitations are cost-effective. For the 
same amount of cost, organized screening pro- 
grammes are always superior to spontaneous screen- 
ing. Discouraging spontaneous screening in The 
Netherlands and replacing it by efficient policy with 
7 invitations per woman would save over 20 million 
guilders (financial costs) per year, without any rise in 
cervical cancer mortality. The Dutch public health 
insurance funds are trying to restrict spontaneous 
screening, except for situations in which women have 
possible cervical cancer-related symptoms, a small 
minority of the cases. 
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